skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

ARIAD to Be Acquired by Takeda in $5.2 Billion Transaction

Paul, Weiss is representing ARIAD Pharmaceuticals, Inc. in its proposed $5.2 billion acquisition by Takeda Pharmaceutical Company Limited. Under the terms of the agreement ARIAD stockholders will receive $24.00 in cash for each share of ARIAD common stock they own. The all-cash transaction has been approved unanimously by the boards of directors of both companies and is expected to close by the end of February.

The Paul, Weiss team included corporate partners Scott Barshay, Jeffrey Marell, Manuel Frey, Brian Lavin and John Kennedy and counsel Patricia Vaz de Almeida and Edward So; employee benefits partner Andrew Gaines and counsel Jason Ertel; intellectual property partner Chuck Googe; tax partner David Sicular; litigation partners Andrew Forman, Rick Rule and Daniel Toal; real estate partner Peter Fisch; antitrust counsel Marta Kelly; environmental counsel William O'Brien; and international trade counsel Richard Elliott.

January 9, 2017

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy